TrialThe clinical respiratory journal2025

Ruxolitinib for Emergency Treatment of COVID-19-Associated Cytokine Storm: Findings From an Expanded Access Study.

Jeffrey Weinstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.